Co-Diagnostics, Inc. (NASDAQ:CODX – Get Free Report) was the recipient of a large increase in short interest in October. As of October 30th, there was short interest totaling 981,329 shares, an increase of 49.5% from the October 15th total of 656,373 shares. Based on an average daily volume of 438,760 shares, the short-interest ratio is presently 2.2 days. Currently, 10.5% of the shares of the stock are sold short.
Institutional Trading of Co-Diagnostics
A hedge fund recently bought a new stake in Co-Diagnostics stock. Susquehanna International Group LLP bought a new position in Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 31,239 shares of the company’s stock, valued at approximately $97,000. Susquehanna International Group LLP owned 0.85% of Co-Diagnostics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 14.99% of the company’s stock.
Wall Street Analysts Forecast Growth
CODX has been the subject of several recent analyst reports. Maxim Group raised Co-Diagnostics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 18th. Wall Street Zen raised Co-Diagnostics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Finally, Weiss Ratings lowered Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $45.00.
Read Our Latest Research Report on Co-Diagnostics
Co-Diagnostics Stock Performance
CODX stock traded down $0.03 during midday trading on Tuesday, reaching $0.19. 860,347 shares of the company were exchanged, compared to its average volume of 2,582,451. The company has a market cap of $2.02 million, a price-to-earnings ratio of -0.02 and a beta of 3.15. Co-Diagnostics has a 1-year low of $0.17 and a 1-year high of $13.54. The stock’s 50-day simple moving average is $0.78 and its 200 day simple moving average is $2.07.
Co-Diagnostics (NASDAQ:CODX – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.24. The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.17 million. Co-Diagnostics had a negative return on equity of 322.92% and a negative net margin of 5,530.54%.
Co-Diagnostics Company Profile
Co-Diagnostics, Inc. is a molecular diagnostics company that develops technologies and tests for detecting infectious diseases. Based in Salt Lake City, Utah, the company’s work centers on its proprietary CoPrimer technology, used to design assays for polymerase chain reaction (PCR) testing. Its products include PCR-based diagnostic tests and related instruments, including the Co-Dx PCR platform. The company has developed tests for a range of infectious diseases, with product availability and regulatory status varying by market.
Further Reading
- Five stocks we like better than Co-Diagnostics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
